[What is new … in the treatment of invasive mycosis: COVID-19-associated pulmonary aspergillosis].
作者信息
Scharf Christina, Zoller Michael, Liebchen Uwe
机构信息
Klinik für Anästhesiologie, LMU Klinikum, Marchioninistraße 15, 81377, München, Deutschland.
出版信息
Anaesthesist. 2021 May;70(5):432-433. doi: 10.1007/s00101-021-00931-w. Epub 2021 Feb 26.
Abstract
摘要
相似文献
1
[What is new … in the treatment of invasive mycosis: COVID-19-associated pulmonary aspergillosis].[侵袭性真菌病治疗的新进展……：新型冠状病毒肺炎相关肺曲霉病]
Anaesthesist. 2021 May;70(5):432-433. doi: 10.1007/s00101-021-00931-w. Epub 2021 Feb 26.
2
Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis.迈向新型冠状病毒肺炎相关肺曲霉病伏立康唑给药的个性化与综合管理
Crit Care. 2021 Apr 20;25(1):152. doi: 10.1186/s13054-021-03568-8.
3
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.定义和管理新型冠状病毒肺炎相关肺曲霉病：2020年欧洲临床微生物与感染性疾病学会/国际人类与动物真菌学会研究和临床指南共识标准
Lancet Infect Dis. 2021 Jun;21(6):e149-e162. doi: 10.1016/S1473-3099(20)30847-1. Epub 2020 Dec 14.
4
Assessing the entire landscape of antifungal immune response to COVID-19-associated pulmonary aspergillosis.评估针对新型冠状病毒肺炎相关肺曲霉病的抗真菌免疫反应全貌。
Lancet Microbe. 2024 Aug;5(8):100861. doi: 10.1016/S2666-5247(24)00076-4. Epub 2024 Apr 23.
5
Chronic pulmonary aspergillosis: help is on the way.慢性肺曲霉病：援助即将到来。
Lancet Respir Med. 2016 Feb;4(2):83. doi: 10.1016/S2213-2600(16)00013-8.
6
Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus infection.泊沙康唑用于慢性肺曲霉病：应对唑类耐药曲霉感染威胁的下一个策略。
Clin Infect Dis. 2010 Dec 15;51(12):1392-4. doi: 10.1086/657307. Epub 2010 Nov 5.
7
COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report.一名日本男性的新型冠状病毒肺炎相关肺曲霉病：病例报告
J Infect Chemother. 2021 Jun;27(6):911-914. doi: 10.1016/j.jiac.2021.02.026. Epub 2021 Feb 25.
8
Chronic Nodular Pulmonary Aspergillosis in a Patient with Rheumatoid Arthritis.一名类风湿关节炎患者的慢性结节性肺曲霉病
Intern Med. 2019;58(7):979-984. doi: 10.2169/internalmedicine.1918-18. Epub 2019 Apr 1.
9
Risk of COVID-19-associated pulmonary aspergillosis: time for a nuanced approach to antifungal prophylaxis?2019冠状病毒病相关肺曲霉病的风险：是时候采取细致入微的抗真菌预防方法了吗？
Lancet Respir Med. 2024 Mar;12(3):183-185. doi: 10.1016/S2213-2600(23)00435-6. Epub 2024 Jan 4.
10
Are respiratory complications more likely in patients with pulmonary aspergillosis treated with echinocandins in the setting of neutrophil influx?在中性粒细胞流入的情况下，接受棘白菌素治疗的肺曲霉病患者发生呼吸道并发症的可能性是否更高？
Virulence. 2014 Apr 1;5(3):375-7. doi: 10.4161/viru.28291. Epub 2014 Feb 25.
本文引用的文献
1
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.定义和管理新型冠状病毒肺炎相关肺曲霉病：2020年欧洲临床微生物与感染性疾病学会/国际人类与动物真菌学会研究和临床指南共识标准
Lancet Infect Dis. 2021 Jun;21(6):e149-e162. doi: 10.1016/S1473-3099(20)30847-1. Epub 2020 Dec 14.
2
Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study.COVID-19 气管插管患者侵袭性肺曲霉病的流行病学：一项前瞻性研究。
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614. doi: 10.1093/cid/ciaa1065.
3
Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis.应对和减轻 COVID-19 相关肺曲霉病的风险。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.02554-2020. Print 2020 Oct.
Zotero 插件